BOS 0.00% 1.5¢ biosignal limited

dental breakthrough, page-17

  1. 869 Posts.
    lightbulb Created with Sketch. 24
    Hear Hear Saracen.

    BOS is always clear on the long path to market for their products. Testing and registration takes years, even when everything goes right.

    It doesn't always go right. Remember the lens announcement of being 100% effective? Had lenses worked, they would have still faced years waiting for approval from FDA and equivalent bodies.

    It's not all bad though. Even potential products have a value. Also, there has been many years of testing done on some of the compounds. If compounds are of a known type or stable nature the path to registration can be quicker (maybe 2 years rather than 4).

    Having been in BOS for years, i do sense progress, slowly, slowly. The 'exciting' thing is success and failure often pivots on technical problems as much as the compound itself. Anti-fouling may fail for lack of an effective biomaterial. But later success in another field, say covalently bonding to a dental resin, may herald success in previously shelved research. Progress may be slow, but i confess to finding it immensely interesting.
 
watchlist Created with Sketch. Add BOS (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.